# EDGAR Filing Document

**Accession Number:** 0001179697
**File Stem:** 0000914190-26-000042
**Filing Date:** 2026-3
**Character Count:** 7863
**Document Hash:** 4fe7792cd879cd3f4f0c9f16072345f0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000914190-26-000042.hdr.sgml**: 20260318

**ACCESSION NUMBER**: 0000914190-26-000042

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260316

**FILED AS OF DATE**: 20260318

**DATE AS OF CHANGE**: 20260318

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Amron Arthur H
- **CENTRAL INDEX KEY:** 0001179697

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-32288
- **FILM NUMBER:** 26770522

**MAIL ADDRESS:**
- **STREET 1:** 19 CHESTERFIELD ROAD
- **CITY:** SCARSDALE
- **STATE:** NY
- **ZIP:** 10583

**FORMER NAME:**
- **FORMER CONFORMED NAME:** AMRON ARTHUR H
- **DATE OF NAME CHANGE:** 20020808
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NEPHROS INC
- **CENTRAL INDEX KEY:** 0001196298
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 133971809
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 380 LACKAWANNA PLACE
- **CITY:** SOUTH ORANGE
- **STATE:** NJ
- **ZIP:** 07079
- **BUSINESS PHONE:** 201.343.5202

**MAIL ADDRESS:**
- **STREET 1:** 380 LACKAWANNA PLACE
- **CITY:** SOUTH ORANGE
- **STATE:** NJ
- **ZIP:** 07079

## Ex-24

```

POWER OF ATTORNEY

	The undersigned hereby constitutes and appoints Christopher Melsha,
and Edward Peilen, or either of them acting alone, the undersigned's true
and lawful attorney-in-fact and agent with full power of substitution and
resubstitution, for the undersigned and in the undersigned's name, place
and stead, in any and all capacities, to sign any or all Forms 3, Forms 4
and Forms 5 relating to beneficial ownership of securities of Nephros, Inc.
(the "Issuer"), to file the same, with all exhibits thereto and other
documents in connection therewith, with the Securities and Exchange
Commission and to deliver a copy of the same to the Issuer, granting unto
said attorney-in-fact and agent full power and authority to do and perform
each and every act and thing requisite and necessary to be done in and about
the premises, as fully to all intents and purposes as the undersigned might
or could do in person, hereby ratifying and confirming all said attorneys-in
-fact and agent, or his substitute or substitutes, may lawfully do or cause
to be done by virtue thereof. The undersigned acknowledges that the foregoing
attorney-in-fact, in serving in such capacity at the request of the
undersigned, is not assuming any of the undersigned's responsibilities to
comply with Section 16 of the Securities Exchange Act of 1934.

	This Power of Attorney shall remain in effect until such time as the
undersigned is no longer subject to the provisions of Section 16 of the
Securities Exchange Act of 1934 with respect to securities of the Issuer.

	IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney
to be executed as of this 14th day of November, 2025.

				/s/ Arthur Amron
				Arthur Amron

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Amron Arthur H<br><sub>(Last) (First) (Middle)</sub><br>C/O NEPHROS, INC., 380 LACKAWANNA PLACE<br><sub>(Street)</sub><br>SOUTH ORANGE, NJ 07079<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-03-16 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>NEPHROS INC [ NEPH ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-03-16 |  | A |  | 3610<sup>(1)</sup> | A | $0 | 134882 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $2.14 |  |  |  |  |  |  | <sup>(2)</sup> | 2034-05-14 | Common Stock | 7323 |  | 7323 | D |  |
| Stock Option (Right to Buy) | $1.47 |  |  |  |  |  |  | <sup>(3)</sup> | 2035-01-01 | Common Stock | 7050 |  | 7050 | D |  |

---

### Footnotes:

(1) Shares issued to reporting person in lieu of cash fees for board service.

(2) This option vests as to 2,441 shares on each of 5/14/24, 5/14/25 and 5/14/26.

(3) This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27.

**Signature:** /s/ Christopher Melsha Attorney-in-Fact for Arthur H. Amron pursuant to Power of Attorney filed herewith.  
**Date:** 2026-03-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**